Literature DB >> 33411899

Evolution of Cefiderocol Non-Susceptibility in Pseudomonas aeruginosa in a Patient Without Previous Exposure to the Antibiotic.

Ana Paula Streling1,2, Mohanad M Al Obaidi3,4, William D Lainhart3,4,5, Tirdad Zangeneh3,4, Ayesha Khan1,6,7, An Q Dinh1,8,9, Blake Hanson1,8,9, Cesar A Arias1,7,8,9,10, William R Miller1,8.   

Abstract

We report the emergence of non-susceptibility to cefiderocol from a subpopulation of Pseudomonas aeruginosa recovered from a patient without history of cefiderocol exposure. Whole genome sequencing identified mutations in major iron transport pathways previously associated with cefiderocol uptake. Susceptibility testing should be performed before therapy with siderophore cephalosporins.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  zzm321990 Pseudomonas aeruginosazzm321990 ; antibiotic resistance; cefiderocol

Mesh：

Substances：

Year:  2021        PMID： 33411899      PMCID： PMC8825772          DOI： 10.1093/cid/ciaa1909

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  10 in total

1.  Multilocus sequence typing of total-genome-sequenced bacteria.

Authors:  Mette V Larsen; Salvatore Cosentino; Simon Rasmussen; Carsten Friis; Henrik Hasman; Rasmus Lykke Marvig; Lars Jelsbak; Thomas Sicheritz-Pontén; David W Ussery; Frank M Aarestrup; Ole Lund
Journal:  J Clin Microbiol       Date:  2012-01-11       Impact factor: 5.948

2.  Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC.

Authors:  Gabriel Cabot; Sebastian Bruchmann; Xavier Mulet; Laura Zamorano; Bartolomé Moyà; Carlos Juan; Susanne Haussler; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2014-03-17       Impact factor: 5.191

3.  Clinical Evolution of AmpC-Mediated Ceftazidime-Avibactam and Cefiderocol Resistance in Enterobacter cloacae Complex Following Exposure to Cefepime.

Authors:  Ryan K Shields; Alina Iovleva; Ellen G Kline; Akito Kawai; Christi L McElheny; Yohei Doi
Journal:  Clin Infect Dis       Date:  2020-12-17       Impact factor: 9.079

Review 4.  Approach to the Treatment of Patients with Serious Multidrug-Resistant Pseudomonas aeruginosa Infections.

Authors:  J Nicholas O'Donnell; Monique R Bidell; Thomas P Lodise
Journal:  Pharmacotherapy       Date:  2020-08-17       Impact factor: 4.705

Review 5.  Antimicrobial Resistance in Bacteria: Mechanisms, Evolution, and Persistence.

Authors:  Eirini Christaki; Markella Marcou; Andreas Tofarides
Journal:  J Mol Evol       Date:  2019-10-28       Impact factor: 2.395

6.  Structure and Function of the PiuA and PirA Siderophore-Drug Receptors from Pseudomonas aeruginosa and Acinetobacter baumannii.

Authors:  Lucile Moynié; Alexandre Luscher; Dora Rolo; Daniel Pletzer; Antoni Tortajada; Helge Weingart; Yvonne Braun; Malcolm G P Page; James H Naismith; Thilo Köhler
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

7.  Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins.

Authors:  M Berrazeg; K Jeannot; Véronique Yvette Ntsogo Enguéné; I Broutin; S Loeffert; D Fournier; P Plésiat
Journal:  Antimicrob Agents Chemother       Date:  2015-07-27       Impact factor: 5.191

8.  In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria.

Authors:  Yoshinori Yamano
Journal:  Clin Infect Dis       Date:  2019-11-13       Impact factor: 9.079

9.  TonB-Dependent Receptor Repertoire of Pseudomonas aeruginosa for Uptake of Siderophore-Drug Conjugates.

Authors:  Alexandre Luscher; Lucile Moynié; Pamela Saint Auguste; Dirk Bumann; Lena Mazza; Daniel Pletzer; James H Naismith; Thilo Köhler
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

10.  Cefiderocol for Extensively Drug-Resistant Gram-Negative Bacterial Infections: Real-world Experience From a Case Series and Review of the Literature.

Authors:  Sandra Zingg; G Jacopo Nicoletti; Sabine Kuster; Milena Junker; Andreas Widmer; Adrian Egli; Vladimira Hinic; Parham Sendi; Manuel Battegay; Veronika Bättig; Nina Khanna; Sarah Tschudin-Sutter
Journal:  Open Forum Infect Dis       Date:  2020-05-21       Impact factor: 3.835
  10 in total
  12 in total

Review 1.  Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance.

Authors:  Stamatis Karakonstantis; Maria Rousaki; Evangelos I Kritsotakis
Journal:  Antibiotics (Basel)       Date:  2022-05-27

Review 2.  New Drugs for the Treatment of Pseudomonas aeruginosa Infections with Limited Treatment Options: A Narrative Review.

Authors:  Angela Raffaella Losito; Francesca Raffaelli; Paola Del Giacomo; Mario Tumbarello
Journal:  Antibiotics (Basel)       Date:  2022-04-26

Review 3.  Class C β-Lactamases: Molecular Characteristics.

Authors:  Alain Philippon; Guillaume Arlet; Roger Labia; Bogdan I Iorga
Journal:  Clin Microbiol Rev       Date:  2022-04-18       Impact factor: 50.129

Review 4.  New Perspectives on Antimicrobial Agents: Cefiderocol.

Authors:  Erin K McCreary; Emily L Heil; Pranita D Tamma
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

5.  Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections.

Authors:  Marianna Meschiari; Sara Volpi; Matteo Faltoni; Giovanni Dolci; Gabriella Orlando; Erica Franceschini; Marianna Menozzi; Mario Sarti; Giovanni Del Fabro; Benedetta Fumarola; Francesco Guarneri; Paola Lanza; Silvia Lorenzotti; Barbara Saccani; Liana Signorini; Evelyn Van Hauwermeiren; Milo Gatti; Federico Pea; Francesco Castelli; Cristina Mussini
Journal:  JAC Antimicrob Resist       Date:  2021-12-11

Review 6.  Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa.

Authors:  Ashlan J Kunz Coyne; Amer El Ghali; Dana Holger; Nicholas Rebold; Michael J Rybak
Journal:  Infect Dis Ther       Date:  2022-02-12

Review 7.  β-lactam Resistance in Pseudomonas aeruginosa: Current Status, Future Prospects.

Authors:  Karl A Glen; Iain L Lamont
Journal:  Pathogens       Date:  2021-12-18

8.  Human Serum Proteins and Susceptibility of Acinetobacter baumannii to Cefiderocol: Role of Iron Transport.

Authors:  Casin Le; Camila Pimentel; Fernando Pasteran; Marisel R Tuttobene; Tomás Subils; Jenny Escalante; Brent Nishimura; Susana Arriaga; Aimee Carranza; Vyanka Mezcord; Alejandro J Vila; Alejandra Corso; Luis A Actis; Marcelo E Tolmasky; Robert A Bonomo; Maria Soledad Ramírez
Journal:  Biomedicines       Date:  2022-03-03

Review 9.  Urgent need for novel antibiotics in Republic of Korea to combat multidrug-resistant bacteria.

Authors:  Hyo-Jin Lee; Dong-Gun Lee
Journal:  Korean J Intern Med       Date:  2022-02-28       Impact factor: 2.884

10.  Cefiderocol Activity Against Clinical Pseudomonas aeruginosa Isolates Exhibiting Ceftolozane-Tazobactam Resistance.

Authors:  Patricia J Simner; Stephan Beisken; Yehudit Bergman; Andreas E Posch; Sara E Cosgrove; Pranita D Tamma
Journal:  Open Forum Infect Dis       Date:  2021-06-12       Impact factor: 3.835
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.